CSBR stock icon

Champions Oncology

4.54 USD
+0.17
3.89%
At close Oct 15, 4:00 PM EDT
1 day
3.89%
5 days
-2.78%
1 month
-9.20%
3 months
-9.38%
6 months
-13.19%
Year to date
-21.59%
1 year
-28.05%
5 years
-21.45%
 

About: Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Employees: 306

0
Funds holding %
of 6,740 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

7% more capital invested

Capital invested by funds: $27.8M [Q1] → $29.9M (+$2.05M) [Q2]

0.73% more ownership

Funds ownership: 41.75% [Q1] → 42.49% (+0.73%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

8% less funds holding

Funds holding: 25 [Q1] → 23 (-2) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

73% less call options, than puts

Call options by funds: $17K | Put options by funds: $63K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
32%
upside
Avg. target
$6
32%
upside
High target
$6
32%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Craig-Hallum
Matt Hewitt
33% 1-year accuracy
3 / 9 met price target
32%upside
$6
Buy
Upgraded
12 Sept 2024

Financial journalist opinion

Charts implemented using Lightweight Charts™